Philip C. Mack - Concepedia

Author

Philip C. Mack

Also Known As

Buran, Connie, Kawaguchi, Tomoya, Mack, Philip C., P C Mack, P Mack, P. C. Mack, P. Mack, P.C Mack, P.C. Mack, PHILIP MACK

466

Publications

11.8K

Citations

H-Index

Concepts

All Affiliations

University of California, Davis UC Davis Comprehensive Cancer Center Fred Hutch Cancer Center University of Southern California University of California Davis Medical Center

About

Philip C. Mack is an author at University of California, Davis specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	83	4.2K
2	Health Sciences	12	15	302
3	Engineering	4	4	485
4	Allergy	1	1	15
5	Biochemistry	1	1	15

Philip C. Mack

136

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers Collin M. Blakely, Thomas B.K. Watkins, Wei Wu, Nature Genetics Co-occurring Genetic AlterationsOncologySomatic VariantMedicineGenetics	2017	566
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, Clinical Cancer Research	2018	386
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer Amir Goldkorn, Benjamin Ely, David I. Quinn, Journal of Clinical Oncology	2014	329
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Ramesh K. Ramanathan, Chandra P. Belani, D. A. Singh, Cancer Chemotherapy and Pharmacology HepatologyMedicineBiliary CancerPathologyPhase Ii Study	2009	286
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, Nature Medicine Ras-mapk Dependence UnderliesEml4-alk–positive Lung CancerMedicinePathologyCancer Cell Biology	2015	275
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Clinical Cancer Research EngineeringBiomarker-driven ProtocolAdvanced Lung DiseaseLung Master ProtocolPathology	2015	232
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence Edward M. Messing, Catherine M. Tangen, Seth P. Lerner, JAMA	2018	232
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC Jonathan W. Riess, David R. Gandara, Garrett M. Frampton, Journal of Thoracic Oncology Functional GenomicsEngineeringComprehensive Genomic ProfilingMedicineMolecular Biology	2018	224
Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics David R. Gandara, Tomoya Kawaguchi, John Crowley, Journal of Clinical Oncology	2009	213
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer Tanya B. Dorff, Bryan Goldman, Jacek Pinski, Clinical Cancer Research	2010	209

Page 1